Evaluation of PSA progression after initiation of enzalutamide or abiraterone: Real-world data on metastatic castration-resistant prostate cancer (mCRPC).

Fernando López-Campos,David Lorente,Casilda Llacer Perez,Miguel-Ramirez Backhaus,Paula Peleteiro,Alfonso Gomez-Iturriaga,Iván Henríquez López,Rebeca Lozano,Nuria Romero,Teresa Alonso-Gordoa,Javier Molina-Cerrillo,Joaquin Navarro-Castellón,Ana Castaño,Lira Pelari,Antonio Hernández-Corrales,Virginia Morillo,Raquel Garcia,Carlos Ferrer Albiach,Elena Castro,David Olmos

Evaluation of PSA progression after initiation of enzalutamide or abiraterone: Real-world data on metastatic castration-resistant prostate cancer (mCRPC).

2021

5024Background: PSA value is widely used for the monitoring of treatment outcome in mCRPC in the clinical real-world setting. Early PSA changes are not considered in the definition of PSAProg due t...

Keywords:

real world data
Oncology
Medicine
Enzalutamide
Abiraterone
treatment outcome
Internal medicine
castration resistant
Prostate cancer
PSA PROGRESSION

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations